ValiRx plc (LON:VAL – Get Free Report)’s stock price was down 6.4% during mid-day trading on Thursday . The company traded as low as GBX 2.11 ($0.03) and last traded at GBX 2.20 ($0.03). Approximately 600,319 shares were traded during trading, a decline of 44% from the average daily volume of 1,079,764 shares. The stock had previously closed at GBX 2.35 ($0.03).
ValiRx Trading Down 6.4 %
The business has a fifty day moving average of GBX 2.59 and a 200-day moving average of GBX 3.17. The stock has a market capitalization of £2.91 million, a price-to-earnings ratio of -110.00 and a beta of 0.63. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.64 and a quick ratio of 1.27.
ValiRx Company Profile
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer.
Further Reading
- Five stocks we like better than ValiRx
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Does A&F’s Q2 Earnings Win Point to a Strong Holiday Season?
- What Are Some of the Best Large-Cap Stocks to Buy?
- Best Buy Stock Flashes Bullish Signal, Challenges Remain
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Affirm Shows Buy-Now-Pay-Later Is Here to Stay in Latest Results
Receive News & Ratings for ValiRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx and related companies with MarketBeat.com's FREE daily email newsletter.
